^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRT2527

    i
    Company:
    Prelude Therap
    Drug class:
    CDK9 inhibitor
    Related drugs:
    Apply
    A Study of PRT2527 in Participants With Advanced Solid Tumors (NCT05159518)
    Phase 1
    Prelude Therapeutics
    Completed
    Last update posted :
    12/11/2023
    Initiation :
    02/14/2022
    Primary completion :
    12/06/2023
    Completion :
    12/06/2023
    HER-2 • MYC
    |
    HR positive • HER-2 negative • MYC amplification
    |
    PRT2527